Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...